BACKGROUND: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. METHODS: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade <2. NOX2 and isoprostanes (8-iso-PGF2α) levels, as assessed by enzyme-linked immunoadsorbent assay (ELISA) or by an enzyme immunoassays, respectively, were measured on admission, at 24 h and pre-discharge. RESULTS: NOX2 levels increased from baseline to pre-discharge in patients with angiographic MVO (20.25 (15-24.75) pg/ml vs 25.50 (17-29.25) pg/ml, p=0.02), but not in MR patients (p=0.45), with a significant interaction between baseline and pre-discharge levels among the two groups (p=0.04). The levels of 8-iso-PGF2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). CONCLUSION: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.
BACKGROUND: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. METHODS: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade <2. NOX2 and isoprostanes (8-iso-PGF2α) levels, as assessed by enzyme-linked immunoadsorbent assay (ELISA) or by an enzyme immunoassays, respectively, were measured on admission, at 24 h and pre-discharge. RESULTS:NOX2 levels increased from baseline to pre-discharge in patients with angiographic MVO (20.25 (15-24.75) pg/ml vs 25.50 (17-29.25) pg/ml, p=0.02), but not in MR patients (p=0.45), with a significant interaction between baseline and pre-discharge levels among the two groups (p=0.04). The levels of 8-iso-PGF2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). CONCLUSION:Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.
Authors: Paul Sorajja; Bernard J Gersh; Costantino Costantini; Michael G McLaughlin; Peter Zimetbaum; David A Cox; Eulogio Garcia; James E Tcheng; Roxana Mehran; Alexandra J Lansky; David E Kandzari; Cindy L Grines; Gregg W Stone Journal: Eur Heart J Date: 2005-02-25 Impact factor: 29.983
Authors: Tone Svilaas; Pieter J Vlaar; Iwan C van der Horst; Gilles F H Diercks; Bart J G L de Smet; Ad F M van den Heuvel; Rutger L Anthonio; Gillian A Jessurun; Eng-Shiong Tan; Albert J H Suurmeijer; Felix Zijlstra Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245
Authors: Ralf A Benndorf; Edzard Schwedhelm; Anke Gnann; Raihana Taheri; Ghainsom Kom; Michael Didié; Anna Steenpass; Süleyman Ergün; Rainer H Böger Journal: Circ Res Date: 2008-09-18 Impact factor: 17.367
Authors: Zhengyuan Xia; Kuo-Hsing Kuo; David V Godin; Michael J Walker; Michelle C Y Tao; David M Ansley Journal: Am J Physiol Heart Circ Physiol Date: 2005-06-03 Impact factor: 4.733
Authors: Francesco Violi; Valerio Sanguigni; Roberto Carnevale; Alessandro Plebani; Paolo Rossi; Andrea Finocchi; Claudio Pignata; Domenico De Mattia; Baldassarre Martire; Maria Cristina Pietrogrande; Silvana Martino; Eleonora Gambineri; Anna Rosa Soresina; Pasquale Pignatelli; Francesco Martino; Stefania Basili; Lorenzo Loffredo Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Juergen Kammler; Alexander Kypta; Robert Hofmann; Klaus Kerschner; Michael Grund; Kurt Sihorsch; Clemens Steinwender; Thomas Lambert; Wolfram Helml; Franz Leisch Journal: Clin Res Cardiol Date: 2008-10-30 Impact factor: 5.460